

REMARKS

Claims 4, 12 and 17-19 have been amended. Claims 21-48 have been added to the application. No other claims have been added or deleted. With entry of this amendment claims 1-48 will be pending.

Claims 4 and 12 have been amended to correct a typographical error. The word "simvastin" has been replaced with "simvastatin." Support for this amendment can be found on page 5, line 12 of the specification.

Claims 17-19 have been amended to correct a typographical error. The term "HMB-CoA" has been replaced with "HMG-CoA." Support for this amendment can be found on page 4, lines 15-18 of the specification.

Claims 21-48 have been copied from U.S. Application No. 11/114,512 ("the '512 application") which published as U.S. Publication No. 2005/0239871 on October 27, 2005. Applicant expressly reserves the right to provoke an interference with the '512 application at a later date.

Entry of the Amendment and examination on the merits are respectfully requested.

Respectfully submitted,

A handwritten signature in black ink, appearing to read "G. J. Hartwig", with a long horizontal line extending to the left.

Gregory J. Hartwig
Reg. No. 46,761

Docket No. 017425-9004-00

Michael Best & Friedrich LLP
100 East Wisconsin Avenue, Suite 3300
Milwaukee, Wisconsin 53202-4108
(414) 271-6560

T:\CLIENTA\017425\9004\A1814014.1